Legal 500
Log in or register
  • Rankings

    • Jurisdictions
    • Submissions
    • Future Lawyers
  • Firms & Lawyers

    • Service Providers
    • Barristers’ Sets
    • Networks
    • Interview with…
  • In-House

    • In-House Content
    • GC Powerlist
  • Knowledge Centre

    • Data Products
    • Legal Business
    • Market Intelligence
    • About us

      • Legal 500
      • FAQs
      • Marketing
      • Careers
      • Trust Centre
      • Contact us
  • Comparative Guides
  • Events
  • Legal 500 TV

About us

  • Legal 500
  • FAQs
  • Marketing
  • Careers
  • Trust Centre
  • Contact us
  • Deutschland DE
  • Paris FR
  • Rankings

    • Jurisdictions
    • Submissions
    • Future Lawyers
  • Firms & Lawyers

    • Service Providers
    • Barristers’ Sets
    • Networks
    • Interview with…
  • In-House

    • In-House Content
    • GC Powerlist
  • Knowledge Centre

    • Data Products
    • Legal Business
    • Market Intelligence
    • About us

      • Legal 500
      • FAQs
      • Marketing
      • Careers
      • Trust Centre
      • Contact us
  • Comparative Guides
  • Events
  • Legal 500 TV

About us

  • Legal 500
  • FAQs
  • Marketing
  • Careers
  • Trust Centre
  • Contact us
  • Deutschland DE
  • Paris FR

© 2026 Legalease Ltd. All rights reserved

Registered company in England & Wales No. 02427356 VAT GB 321 5727 22

Registered address: 188 Fleet Street, London, EC4A 2AG

  • Legal 500 Trust Centre
  • Contact Us
  • home
  • Market Intelligence
  • Search

265 results found

Use advanced search filters to refine your search

2 filters applied

Advanced search filters

Topics
Countries
Contributor

Start typing to add contributors

Content type
Show options
  • Article

    2022-2023 China Medical Device License-In/Out Project Core Clause Data Analysis

    License-in/out has become the most common way for innovative drug and medical device (including medical aesthetic) companies to collaborate on the development of related technologies...
    ChinaFood, Drugs, Healthcare, Life Sciences
    Han Kun Law Offices
    Han Kun Law Offices
  • Article

    远程医疗的法律概念和内容浅析

    提出了"远程医疗会诊"的概念,远程医疗会诊是应用计算机及网络、通讯技术进行异地医疗咨询活动,属于医疗行为,必须在取得《医疗机构执&#
    ChinaFood, Drugs, Healthcare, Life Sciences
    DeHeng Law Offices
    DeHeng Law Offices
Article

Han Kun • Opinion | Interpret The New Regulations For The Inspection Of Drug Clinical Trial Institutions In The Post-"722 Storm" Era

On December 1, 2019, the Drug Administration Law and the Vaccine Administration Law officially came into effect, and the relevant regulations adjusted the management...
ChinaFood, Drugs, Healthcare, Life Sciences
Han Kun Law Offices
Han Kun Law Offices
  • Article

    Han Kun • Opinion | The New Ethical Review Regulations Focus On Quick Comments

    On February 27, 2023, the National Health Commission, together with the Ministry of Education, the Ministry of Science and Technology, and the State Administration of Traditional Chinese Medicine...
    ChinaFood, Drugs, Healthcare, Life Sciences
    Han Kun Law Offices
    Han Kun Law Offices
  • Article

    拒不执行新冠疫情防治措施之刑行立案处罚标准简析——结合既有通报案例

    拒不执行新冠疫情防治措施之刑行立案处罚标准简析...
    ChinaCriminal Law
    DeHeng Law Offices
    DeHeng Law Offices
  • Article

    汉坤 • 观点 | CAR-T/NK监管路在何方 — 体细胞临床研究工作指引(征求意见稿)要点解读

    2023年5月9日,国家卫健委科教司发布《体细胞临床研究工作指引(征求意见稿)》(" 《征求意见稿》"),并面向社会公开征求意见。体细胞治疗
    ChinaFood, Drugs, Healthcare, Life Sciences
    Han Kun Law Offices
    Han Kun Law Offices
  • Article

    里程碑式判决:经营者集中行政诉讼"第一案"代理有感

    某某药业有限公司("某某药业公司")与北京某药业有限公司("北京某药业公司")之间就股权交易的争议由来已久。双方争议涉及股权买卖纠纷
    ChinaAntitrust/Competition Law
    AnJie Broad Law Firm
    AnJie Broad Law Firm
  • Article

    观点 | 生命科学行业License-In/Out合同争议要点分析(二):适应症变更、监管要求变更、合同变更或解除

    被许可方</strong>认为,适应症变更会在很大程度上浪费先前在适应症X上的研发投入。适应症变更后,许多临床前研究需要重做,也需要重新进行IND申
    ChinaFood, Drugs, Healthcare, Life Sciences
    Han Kun Law Offices
    Han Kun Law Offices
  • Article

    新冠疫情期间刑事高发领域典型案例汇编

    自新型冠状病毒感染的疫情发生以来,全国上下形成了万众一心抗击疫情的高潮。
    ChinaCriminal Law
    DeHeng Law Offices
    DeHeng Law Offices
  • Article

    药品反垄断风险"划重点":‌解读征求意见稿,‌洞悉未来合规要点

    2024年8月9日,国家市场监督管理总局发布《关于药品领域的反垄断指南(征求意见稿)》("征求意见稿")。
    ChinaAntitrust/Competition Law
    AnJie Broad Law Firm
    AnJie Broad Law Firm
  • Article

    "新冠肺炎"疫情下的邮轮业:应急卫生处置与船舶避难相关法律问题初探

    2020年初新冠状病毒爆发以来...
    ChinaFood, Drugs, Healthcare, Life Sciences
    DeHeng Law Offices
    DeHeng Law Offices
  • Article

    汉坤 • 观点 | 从药械产品全生命周期视角解读License-in/out许可交易项目合作条款要点

    创新药械的研发,是一场依托于企业团队的专业技术实力、满载着从业人员的热情与信念、又充满了各种冒险与挑战的旅程,结天时地利人和
    ChinaFood, Drugs, Healthcare, Life Sciences
    Han Kun Law Offices
    Han Kun Law Offices
  • Article

    "新冠"疫情期间行政处罚高发领域典型案例汇编

    自新型冠状病毒感染的疫情发生以来...
    ChinaFood, Drugs, Healthcare, Life Sciences
    DeHeng Law Offices
    DeHeng Law Offices
  • Article

    Measures For Supervision And Administration Of Online Sales Of Drugs: Analysis Of Key Aspects And Impacts

    Fast-growing e-commerce has changed lifestyles and invented new ways of consumption, amid which demand has rapidly increased for Internet-based medical services such as online drug sales...
    ChinaFood, Drugs, Healthcare, Life Sciences
    Han Kun Law Offices
    Han Kun Law Offices
  • Article

    《生命健康法律期刊》第三期发布

    China's pharmaceutical and life sciences regulatory landscape underwent significant transformation in 2026, with major policy updates spanning drug approval processes, medical device quality standards, and healthcare facility management. The National Medical Products Administration introduced priority review pathways for chemical APIs and updated cosmetics registration requirements, while new medical device production standards took effect nationwide.
    ChinaFood, Drugs, Healthcare, Life Sciences
    Jincheng Tongda & Neal
    Jincheng Tongda & Neal
  • Article

    Han Kun • Opinion | The Spring Of Traditional Chinese Medicine? From The "Special Provisions On The Registration And Administration Of Traditional Chinese Medicines", The Characteristic Marketing Evaluation System Of Traditional Chinese Medicine

    In recent years, our country has been vigorously supporting the inheritance, innovation and development of traditional Chinese medicine. In 2019...
    ChinaFood, Drugs, Healthcare, Life Sciences
    Han Kun Law Offices
    Han Kun Law Offices
  • Article

    Han Kun Opinion | Breaking News: 10 Questions And Answers On Pharmaceutical Anti-Corruption In 2023

    Recently, a nationwide campaign to combat corruption in the pharmaceutical sector has been underway in full swing, attracting widespread attention from the industry...
    ChinaFood, Drugs, Healthcare, Life Sciences
    Han Kun Law Offices
    Han Kun Law Offices
  • Article

    2024年NewCo与药械License-in/out项目核心条款数据分析与对比

    License-in/out许可交易已成为创新药品和医疗器械(包括医美)企业加速产品研发和拓展市场的重要战略手段。
    ChinaFood, Drugs, Healthcare, Life Sciences
    Han Kun Law Offices
    Han Kun Law Offices
  • Article

    我国生物安全及人类遗传资源监管合规要点综述(2026版)

    生物安全及人类遗传资源管理是医药企业开展研发、临床试验、生物制品生产及跨境科研合作时需要关注的重要合规领域。本文结合医药企业的主
    ChinaFood, Drugs, Healthcare, Life Sciences
    Jincheng Tongda & Neal
    Jincheng Tongda & Neal
  • Article

    Han Kun • Opinion | Research On Urban Customized Commercial Medical Insurance

    In order to promote the construction of a healthy China, our country has continuously strengthened the top-level design of the universal medical security system.
    ChinaInsurance
    Han Kun Law Offices
    Han Kun Law Offices
  • Showing 241–260 of 265 results

    PreviousNext
    Legal Intelligence Newsletters: sign up for the latest legal and regulatory news on your chosen topics